Extrait

• To identify the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ridaforolimus when administered to children from 6 to less than 18 years of age with advanced solid tumours. • To characterize the pharmacokinetics(levels of study drug in the blood) of ridaforolimus when administered to children from 6 to less than 18 years of age with advanced solid tumours.

Critère d'inclusion

• Advanced solid tumours including lymphoma and tumours of the central nervous system

Liens

• ictrp
• euctr